Early results indicate AstraZeneca/Oxford vaccine is promising

Henrietta Strickland
November 22, 2020

"We were pleased to see that our vaccine was not only well tolerated in older adults, but also stimulated similar immune responses to those seen in younger volunteers".

They will concentrate on the safety of the vaccine and its effectiveness, which has been billed at 95% by Pfizer/BioNTech.

The $25-$37 price point, according to Moderna, puts the vaccine close to a flu shot when it comes to cost, which cost anywhere from $10-$50.

The company is also submitting "rolling submissions" for approval from government agencies around the world.

"While we can not predict how long the FDA's review will take, the FDA will review the request as expeditiously as possible", FDA Commissioner Stephen Hahn said in a statement. "We want to deliver to Europe and are in constructive talks".

In contrast, vaccines developed by Pfizer/BioNTech and Moderna use a new technology called synthetic messenger RNA to activate the immune system against the virus and require far colder storage. There are now no licensed mRNA vaccines. This corresponds to an efficacy of 94.5%.

Vials of the Oxford coronavirus vaccine
Vials of the Oxford coronavirus vaccine

However, it is still unclear how long immunity to the infection will last as the participants will need to be monitored longer. It indicated that individuals over all age bunches appeared to respond equally well to the vaccine jab.

The University of Oxford and AstraZeneca's vaccine included demographics in their study.

"As a result, it is crucial that COVID-19 vaccines are tested in this group who are also a priority group for immunization", he said in a news release from the journal The Lancet.

Coronavirus: On November 16, 2020, United States biotech company Moderna announced a vaccine against COVID-19 that is 94.5% effective.

The University of Oxford confirmed that the Covid-19 vaccine it's developing with AstraZeneca Plc produced strong immune responses in older adults in an early study, with pivotal findings from the final phase of trials expected in the coming weeks. These first vaccinations are part of a special emergency use program authorized by Beijing in July.

While high-risk groups will be the first vaccinated, the USA government hopes that there will be enough vaccines by April 2021 to offer it to the broader population and provide high coverage by the summer.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER